Status:
COMPLETED
Prevalence of Vertebral Fractures in Patients With Type 1 Diabetes
Lead Sponsor:
CHU de Quebec-Universite Laval
Conditions:
Diabetes Mellitus, Type 1
Bone Fracture
Eligibility:
All Genders
20+ years
Brief Summary
Background : Type 1 diabetes is associated with an increased risk of fractures. The mechanisms accounting for this bone fragility are not yet fully understood. The lower bone mineral density (BMD) obs...
Eligibility Criteria
Inclusion
- Individuals with type 1 diabetes
- Diagnosis of type 1 diabetes for at least 5 years;
- Age 20 years and older.
Exclusion
- Pregnancy or breastfeeding;
- Conditions associated with bone disease (significant liver disease, intestinal malabsorption other than celiac disease, organ transplant, active cancer, rheumatoid arthritis, hyperthyroidism, hypothyroidism with abnormal thyroid-stimulating hormone (TSH), hyperparathyroidism, hypoparathyroidism, acromegaly, Cushing syndrome, adrenal insufficiency);
- Any of these medications in the past 6 months : glucocorticoids ≥ 7,5 mg prednisone/day or equivalency ≥ 3 months, aromatase inhibitors, antiandrogens, antiepileptic drugs, anticoagulants, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, thiazolidinediones;
- Past medical history of traumatic vertebral fracture;
- Inability to consent.
- Healthy controls
- Inclusion Criteria:
- Age 20 years and older.
Key Trial Info
Start Date :
July 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 2 2021
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT04064437
Start Date
July 29 2019
End Date
March 2 2021
Last Update
February 13 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de recherches cliniques de Montréal (IRCM)
Montreal, Quebec, Canada, H2W 1R7
2
Centre de recherche du CHU de Québec - Université Laval
Québec, Canada, G1V 4G2